FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Ekman Lars   2. Issuer Name and Ticker or Trading Symbol AMARIN CORP PLC\UK [AMRN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O AMARIN PHARMA, INC., 1430 ROUTE 206 3. Date of Earliest Transaction (Month/Day/Year) 03/04/2019 (Street) BEDMINSTER, NJ 07921 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares (1) (2) 03/04/2019   M   19,584 A $ 1.03 19,584 D   Ordinary Shares (1) (2) 03/04/2019   M   6,390 A $ 1.87 25,974 D   Ordinary Shares (1) (2) 03/04/2019   M   28,500 A $ 1.87 54,474 D   Ordinary Shares (1) (2) 03/04/2019   M   35,258 A $ 2.19 89,732 D   Ordinary Shares (1) (2) 03/04/2019   M   17,358 A $ 2.5 107,090 D   Ordinary Shares (1) (2) 03/04/2019   M   28,287 A $ 2.5 135,377 D   Ordinary Shares (1) (2) 03/04/2019   S   98,677 D $ 21.1607 (3) 36,700 D   Ordinary Shares (1) (2) 03/04/2019   S   36,700 D $ 21.712 (4) 0 D (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (Right to Buy)

$ 1.03

03/04/2019

M

19,584

(6)

02/10/2020

Ordinary Shares (2)

19,584

$ 0

0

D

Stock Option (Right to Buy)

$ 1.87

03/04/2019

M

6,390

(6)

03/11/2024

Ordinary Shares (2)

6,390

$ 0

0

D

Stock Option (Right to Buy)

$ 1.87

03/04/2019

M

28,500

(6)

03/11/2024

Ordinary Shares (2)

28,500

$ 0

0

D

Stock Option (Right to Buy)

$ 2.19

03/04/2019

M

35,258

(6)

07/11/2026

Ordinary Shares (2)

35,258

$ 0

0

D

Stock Option (Right to Buy)

$ 2.5

03/04/2019

M

17,358

(6)

07/06/2025

Ordinary Shares (2)

17,358

$ 0

0

D

Stock Option (Right to Buy)

$ 2.5

03/04/2019

M

28,287

(6)

07/06/2025

Ordinary Shares (2)

28,287

$ 0

0

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Ekman Lars C/O AMARIN PHARMA, INC. 1430 ROUTE 206 BEDMINSTER, NJ 07921	X

Signatures

/s/ Joseph Kennedy, by power of attorney		03/06/2019
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted in 2018 by the Reporting Person in accordance with the requirements for such plans described in the Company's Annual Report on Form 10-K.
(2)	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(3)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.48 to $21.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
(4)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.48 to $22.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
(5)	Please see the section titled "Remarks" below for additional information.
(6)	The stock option granted to the Reporting Person is fully vested as of the date hereof.
Remarks: This number does not represent the aggregate number of Ordinary Shares of the Issuer this Reporting Person holds or has a right to acquire in the form of stock options and restricted stock units granted to such Reporting Person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.